Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,617.10 -329.83 (-0.85%) Hang Seng
19,195.60 -25.02 (-0.13%) FTSE 100
8,348.38 -68.07 (-0.81%) Bitcoin USD
70,106.80 -184.62 (-0.26%) CMC Crypto 200
1,513.12 -13.30 (-0.87%)
DYN May 2024 20.000 put
| Previous close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 20.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
GlobeNewswireDyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and
ZacksDyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
BenzingaWhy Is Dyne Therapeutics Stock Soaring On Monday?
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Earlier this year, Dyne Therapeutics released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseli
